5 new development(s) in neoantigen vaccines today.
Late last week, the drug makers Merck and Cambridge-based Moderna announced that patients who received their melanoma vaccine after surgery were 42 percent less likely to have a recurrence or die within two years than those who did not receive the treatment. And, earlier this mon…
[RECRUITING · PHASE1 · Metaclipse Therapeutics Corporation] The goal of this clinical trial is to learn if an experimental, personalized cancer vaccine called TMV vaccine is safe and to find the best dose to study in future trials. The study includes adults with head and neck squ…
by European Society for Medical Oncology edited by Lisa Lock, reviewed by Andrew Zinin This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility: Adding a pers…
On October 26, 2026, Moderna Inc (NASDAQ: MRNA) CEO Stephane Bancel expressed optimism about the company’s personalized cancer vaccine, intismeran autogene, following phase 3 melanoma trial results that fell short of investor expectations. Bancel emphasized the vaccine’s potentia…
/content/dam/corporate/images/news-and-opinion/news/2026/October/georginalongtimbauer.jpeg Professor Georgina Long to present results of a melanoma vaccine trial that reduces the risk of recurrence or death by 42 percent 2000.1333.2x.jpeg 4000w, 1280.1280.jpeg 1280w, 440.293.2x.j…
neoag.ai tracks clinical, commercial, and AI-methods movement across personalized cancer vaccines, trial activity, TCR/pMHC tools, and market catalysts. Sources are linked inline, synthesized locally, and organized for biotech, investor, and research readers.